Clinical Trials
5 trialsNCT00364780 2022-05-13
Study of XL647 in Subjects With Non-Small-Cell Lung Cancer
Kadmon Corporation, LLC
Phase 2 Completed
NCT00522145 2022-05-13
Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib
Kadmon Corporation, LLC
Phase 2 Completed
NCT01487174 2022-05-13
KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy
Kadmon Corporation, LLC
Phase 3 Terminated
NCT02616393 2022-03-16
Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases
Kadmon Corporation, LLC
Phase 2 Completed
NCT00704392 2015-08-20
Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors
Exelixis
Phase 1 Withdrawn